InVivo Therapeutics

The mission of InVivo Therapeutics is to provide society with superior neurological products and services by delivering novel approaches to the treatment of disease that will improve the quality of life and satisfy the needs of those who live with spinal cord injury. We also seek to empower our employees to create new treatment options for spinal cord injuries with the expectation that they will have the opportunity to make a difference in the lives of all people impacted by these injuries. Our business is preserving and improving human life. We value, above all, our ability to serve everyone who can benefit from the appropriate use of our products and services, thereby providing lasting consumer satisfaction. We recognize that our ability to excel and to most competitively meet society’s and customers’ needs depends on the integrity, knowledge, imagination/creativity, skill, diversity, practicality and teamwork of our employees, and we value these qualities above all else. To this end, we strive to create an environment of mutual respect, encouragement and teamwork—an environment that rewards commitment and performance and is responsive to the needs of our employees and their families. Dr. Langer was awarded the 2006 National Medal of Science by President George W. Bush. InVivo Therapeutics Receives Prestigious 2011 Apple Award for Top Publication in Breakthrough Spinal Cord Injury Research
Type
Public
HQ
Cambridge, US
Founded
2005
Employees
30 (est)+8%
InVivo Therapeutics was founded in 2005 and is headquartered in Cambridge, US

Key People at InVivo Therapeutics

Christopher McNulty

Christopher McNulty

Vice President, Business Development
Brian Hess

Brian Hess

Chief Technology Officer
Steven F. McAllister

Steven F. McAllister

Interim CFO
Kenneth DiPietro

Kenneth DiPietro

Director
Mark D. Perrin

Mark D. Perrin

CEO/Director
John A. McCarthy, Jr.

John A. McCarthy, Jr.

Director/Non-Executive Chairman of the Board

InVivo Therapeutics Locations

Cambridge, US

InVivo Therapeutics Metrics

InVivo Therapeutics Summary

Market capitalization

$157 M

Closing share price

$4.75
InVivo Therapeutics's latest market capitalization is $157 M.

InVivo Therapeutics Market Value History

InVivo Therapeutics Online Presence

InVivo Therapeutics News

InVivo Therapeutics Company Life

You may also be interested in